

# Clinical trials of exenatide 20g

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 diabetes type 2

| Trial  | Treatments   | Patients  | Trials design and methods  |
|--|--|---|--|
| <b>exenatide 20g vs glibenclamide</b>  |  |   |  |
| <a href="#">Derosa , 2010</a><br>n=63/65<br>follow-up:   | exenatide 10 microg twice a day<br>versus<br>glibenclamide 5 mg three times a day  | patients with uncontrolled type 2 diabetes mellitus receiving therapy with metformin  |  |
| <b>exenatide 20g/d vs placebo</b>  |  |   |  |
| <a href="#">Apoian , 2010</a><br>n=96/98<br>follow-up: 24 weeks                                      | 10 microg exenatide twice daily injection + lifestyle modification program<br>versus<br>placebo + lifestyle modification program | overweight or obese participants with type 2 diabetes treated with metformin and/or sulfonylurea  | Parallel groups<br>double-blind  |
| <a href="#">H8O-MC-GWBJ, 9698, 20g/d , 2008</a> <i>unpublished</i><br>n=78/78<br>follow-up: 24 weeks | exenatide twice daily 10 g for 24 weeks<br>versus<br>placebo   | Drug-Naive Patients with Type 2 Diabetes and inadequate glycemic control through diet and exercise  | Parallel groups<br>double-blind<br>4 countries                                 |
| <b>exenatide 20g/d vs placebo (add on insulin)</b>   |  |   |  |
| <a href="#">Buse , 2011</a><br>[NCT00765817]<br>n=138/123<br>follow-up: 30 weeks                     | twice-daily 10 g exenatide injections<br>versus<br>placebo (on top insulin glargine)   | Adults with type 2 diabetes and an HbA1c level of 7.1% to 10.5% who were receiving insulin glargine alone or in combination with metformin or pioglitazone (or both agents) | Parallel groups<br>double-blind<br>Greece, Israel, Mexico, United Kingdom, USA |
| <b>exenatide 20g/d vs placebo (add on MET)</b>   |  |   |  |
| <a href="#">DeFronzo 20g/d , 2005</a><br>[NCT00039013]<br>n=NA<br>follow-up: 30 weeks                | Exenatide 1020 g daily<br>versus<br>Placebo on-top of Metformin  | patients with type 2 diabetes failing to achieve glycemic control with maximally effective metformin doses  | Parallel groups<br>double blind<br>USA   |
| <b>exenatide 20g/d vs placebo (add on MET+/-SU)</b>  |  |   |  |
| <a href="#">Gao , 2009</a><br>[NCT00324363]<br>n=234/232<br>follow-up: 16 weeks                      | exenatide 5 mg then 10 mg twice-daily for 4 and 12 weeks<br>versus<br>placebo  | Asian descent with type 2 diabetes and inadequate glycemic control taking metformin alone or Met and sulfonylureas  | Parallel groups<br>double-blind<br>4 countries                                 |
| <b>exenatide 20g/d vs placebo (add on SU)</b>  |  |   |  |

continued...

| <b>Trial</b>  | <b>Treatments</b>   | <b>Patients</b>   | <b>Trials design and methods</b>  |
|---|---|---|---|
| Buse 20g/d , 2004<br>n=129/123<br>follow-up: 30 weeks                     | Exenatide 10g twice daily<br>versus<br>Placebo on-top of SU   | patients with type 2 diabetes failing<br>maximally effective doses of a<br>sulfonylurea as monotherapy                    | double blind (not adequate)<br>US                                       |
| <b>exenatide 20g/d vs placebo (add on SU+MET)</b>                         |   |   |   |
| Kendall 20g/d , 2005<br>[NCT00035984]<br>n=241/247<br>follow-up: 30 weeks | Exenatide 10 g bid<br>versus<br>Placebo on-top of<br>sulphonylureas+metformin   | patients with type 2 diabetes unable to<br>achieve glycemc control with<br>metformin-sulfonylurea combination<br>therapy  | Parallel groups<br>double blind<br>USA                                  |
| <b>exenatide 20g/d vs placebo (add on TZD+/-MET)</b>                      |   |   |   |
| Zinman 20g/j , 2007<br>[NCT00099320]<br>n=121/112<br>follow-up: 16 weeks  | Exenatide 20 g daily<br>versus<br>Placebo on-top of<br>thiazolidinediones+/-metformin   | patients with type 2 diabetes that was<br>suboptimally controlled with TZD<br>treatment (with or without metformin)       | double blind<br>Canada, Spain, and the United States                    |
| Zinman 20g/j A<br>MODIFIER , 2007<br>n=121/112<br>follow-up: 16 weeks     | exenatide Subcutaneous abdominal<br>injections of 10 microg twice daily<br>versus<br>placebo  | patients with type 2 diabetes that was<br>suboptimally controlled with TZD<br>treatment (with or without metformin)       | Parallel groups<br>double-blind<br>Canada, Spain, and the United States |
| <b>exenatide 20g/d vs BIAsp 30 daily</b>                                  |   |   |   |
| Bergenstal (once daily) ,<br>2009<br>n=NA<br>follow-up: 24 weeks          | exenatide(5 microg BID for 4 weeks and<br>10 microg BID thereafter)<br>versus<br>biphasic insulin aspart 70/30 (BIAsp 30)<br>30 QD (12 U before supper)   | subjects with type 2 diabetes mellitus<br>insulin naive, not achieving glycemc<br>targets with metformin and sulfonylurea | Parallel groups<br>open   |
| <b>exenatide 20g/d vs BIAsp 30 twice daily</b>                            |   |   |   |
| Bergenstal (twice daily) ,<br>2009<br>n=NA<br>follow-up:                  | exenatide (5 microg BID for 4 weeks and<br>10 microg BID thereafter)<br>versus<br>biphasic insulin aspart 70/30 (BIAsp 30)<br>30 BID (12 U divided equally between<br>pre-breakfast and pre-supper) | subjects with type 2 diabetes mellitus<br>insulin naive, not achieving glycemc<br>targets with metformin and sulfonylurea | Parallel groups<br>open   |
| <b>exenatide 20g/d vs insulin (add on SU+MET)</b>                         |   |   |   |
| Heine , 2005<br>n=282/267<br>follow-up: 26 weeks                          | Exenatide 20 g daily<br>versus<br>Insulin on-top of<br>sulphonylureas+metformin   | -   | open  |
| <b>exenatide 20g/d vs insulin (add on SU/MET)</b>                         |   |   |   |

continued...

| <b>Trial</b>   | <b>Treatments</b>   | <b>Patients</b>   | <b>Trials design and methods</b>  |
|--|---|---|---|
| <b>Barnett , 2007</b><br>[NCT00099619]<br>n=136/127<br>follow-up: 16 weeks | Exenatide 20 g daily<br>versus<br>Insulin   | patients with type 2 diabetes   | Cross over<br>open<br>Australia, Greece,Hungary, Italy, Mexico,<br>and Poland |
| <b>Davis , 2007</b><br>[NCT00099333]<br>n=33/16<br>follow-up: 16 weeks     | Exenatide 20 g daily<br>versus<br>Insulin on-top of<br>sulphonylureas/metformin   | patients with type 2 diabetes using<br>insulin in combination with oral<br>antidiabetes agents        | Parallel groups<br>open<br>USA  |
| <b>exenatide 20g/d vs insulin BIAsp twice daily add on SU+MET</b>          |   |   |   |
| <b>Nauck , 2007</b><br>[NCT00082407]<br>n=253/248<br>follow-up: 52 weeks   | Exenatide 20 g daily<br>versus<br>Insulin on-top of<br>sulphonylureas+metformin   | patients with type 2 diabetes who were<br>suboptimally controlled with sulfonylurea<br>and metformin  | Parallel groups<br>open<br>13 countries                                       |
| <b>exenatide 20g/d vs insulin glargine (add on MET)</b>                    |   |   |   |
| <b>Bunck , 2009</b><br>[NCT00097500]<br>n=36/33<br>follow-up: 52 weeks     | exenatide 10g bid<br>versus<br>insulin glargine   | metformin-treated patients with type 2<br>diabetes  | Parallel groups   |
| <b>exenatide 20g/d vs rosiglitazone add on MET</b>                         |   |   |   |
| <b>DeFronzo (EXE vs ROSI) , 2010</b><br>n=45/45<br>follow-up: 20 weeks     | EXE 10 microg b.i.d.<br>versus<br>ROSI 4 mg b.i.d.  | subjects with type 2 diabetes on<br>metformin   | Parallel groups<br>open   |
| <b>exenatide 20g/d vs sitagliptin (add on MET)</b>                         |   |   |   |
| <b>DeFronzo , 2008</b><br>[NCT00477581]<br>n=NA<br>follow-up: 2 weeks      | exenatide subcutaneous injection<br>versus<br>sitagliptin (100 mg QAM) for 2 weeks  | metformin-treated T2D patients  | Cross over<br>double-blind<br>USA   |
| <b>exenatide 20g/d vs weekly exenatide</b>                                 |   |   |   |
| <b>Drucker , 2008</b><br>[NCT00308139]<br>n=NA<br>follow-up: 30 weeks      | 10 mug exenatide administered twice a<br>day<br>versus<br>long-acting release formulation of<br>exenatide 2 mg administered once weekly | patients with type 2 diabetes naive to<br>drug therapy, or on one or more oral<br>antidiabetic agents | Parallel groups<br>open   |

More details and results :

- insulin secretagogues peptides (incretins) for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q381>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled on metformin at <http://www.trialresultscenter.org/>

go-Q509

- antidiabetic drugs for diabetes type 2 in Patients inadequately controlled on MET+SU therapy at <http://www.trialresultscenter.org/go-Q510>
- antidiabetic drugs for diabetes type 2 in patients with insufficient glycaemic control with bitherapy at <http://www.trialresultscenter.org/go-Q511>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled on monotherapy at <http://www.trialresultscenter.org/go-Q512>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled with insulin at <http://www.trialresultscenter.org/go-Q513>

## References

### **Derosa, 2010:**

Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF Exenatide versus glibenclamide in patients with diabetes. *Diabetes Technol Ther* 2010;12:233-40 [20151774] [10.1089/dia.2009.0141](https://doi.org/10.1089/dia.2009.0141)

### **Apovian, 2010:**

Apovian CM, Bergenstal RM, Cuddihy RM, Qu Y, Lenox S, Lewis MS, Glass LC Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. *Am J Med* 2010;123:468.e9-17 [20399326] [10.1016/j.amjmed.2009.11.019](https://doi.org/10.1016/j.amjmed.2009.11.019)

### **H8O-MC-GWBJ, 9698, 20g/d, 2008:**

unpublished

### **Buse, 2011:**

Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AY, Hoogwerf BJ, Rosenstock J Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. *Ann Intern Med* 2011 Jan 18;154:103-12 [21138825] [10.1059/0003-4819-154-2-201101180-00300](https://doi.org/10.1059/0003-4819-154-2-201101180-00300)

### **DeFronzo 20g/d, 2005:**

DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. *Diabetes Care* 2005;28:1092-100 [15855572]

### **Gao, 2009:**

Gao Y, Yoon KH, Chuang LM, Mohan V, Ning G, Shah S, Jang HC, Wu TJ, Johns D, Northrup J, Brodows R Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea. *Diabetes Res Clin Pract* 2009;83:69-76 [19019476] [10.1016/j.diabres.2008.09.037](https://doi.org/10.1016/j.diabres.2008.09.037)

### **Buse 20g/d, 2004:**

Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. *Diabetes Care* 2004;27:2628-35 [15504997]

### **Kendall 20g/d, 2005:**

Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulphonylurea. *Diabetes Care* 2005;28:1083-91 [15855571]

**Zinman 20g/j, 2007:**

Zinman B, Hoogwerf BJ, Durn Garca S, Milton DR, Giaconia JM, Kim DD, Trautmann ME, Brodows RG The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. *Ann Intern Med* 2007;146:477-85 [[17404349](#)]

**Zinman 20g/j A MODIFIER, 2007:**

Zinman B, Hoogwerf BJ, Durn Garca S, Milton DR, Giaconia JM, Kim DD, Trautmann ME, Brodows RG The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. *Ann Intern Med* 2007;146:477-85 [[17404349](#)]

**Bergental (once daily), 2009:**

Bergental R, Lewin A, Bailey T, Chang D, Gylvin T, Roberts V Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea. *Curr Med Res Opin* 2009;25:65-75 [[19210140](#)] [10.1185/03007990802597951](#)

**Bergental (twice daily), 2009:**

Bergental R, Lewin A, Bailey T, Chang D, Gylvin T, Roberts V Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea. *Curr Med Res Opin* 2009;25:65-75 [[19210140](#)] [10.1185/03007990802597951](#)

**Heine, 2005:**

Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widell MH, Brodows RG Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. *Ann Intern Med* 2005;143:559-69 [[16230722](#)]

**Barnett, 2007:**

Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, Trautmann ME Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. *Clin Ther* 2007;29:2333-48 [[18158075](#)] [10.1016/j.clinthera.2007.11.006](#)

**Davis, 2007:**

Davis SN, Johns D, Maggs D, Xu H, Northrup JH, Brodows RG Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. *Diabetes Care* 2007;30:2767-72 [[17595353](#)] [10.2337/dc06-2532](#)

**Nauck, 2007:**

Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A, Brodows R, Trautmann M A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. *Diabetologia* 2007;50:259-67 [[17160407](#)] [10.1007/s00125-006-0510-2](#)

**Bunck, 2009:**

Bunck MC, Diamant M, Cornr A, Eliasson B, Malloy JL, Shaginian RM, Deng W, Kendall DM, Taskinen MR, Smith U, Yki-Jrvinen H, Heine RJ One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. *Diabetes Care* 2009;32:762-8 [[19196887](#)] [10.2337/dc08-1797](#)

Bunck MC, Cornr A, Eliasson B, Heine RJ, Shaginian RM, Taskinen MR, Smith U, Yki-Jrvinen H, Diamant M Effects of exenatide on measures of  $\beta$ -cell function after 3 years in metformin-treated patients with type 2 diabetes. *Diabetes Care* 2011;34:2041-7 [[21868779](#)] [10.2337/dc11-0291](#)

Bunck MC, Cornr A, Eliasson B, Heine RJ, Shaginian RM, Wu Y, Yan P, Smith U, Yki-Jrvinen H, Diamant M, Taskinen MR One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress. *Atherosclerosis* 2010;212:223-9 [[20494360](#)] [10.1016/j.atherosclerosis.2010.04.024](#)

**DeFronzo (EXE vs ROSI), 2010:**

DeFronzo RA, Triplitt C, Qu Y, Lewis MS, Maggs D, Glass LC Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin. *Diabetes Care* 2010;33:951-7 [[20107105](#)] [10.2337/dc09-1521](#)

**DeFronzo, 2008:**

DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. *Curr Med Res Opin* 2008;24:2943-52 [[18786299](#)] [10.1185/03007990802418851](#)

**Drucker, 2008:**

Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter L Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. *Lancet* 2008 Oct 4;372:1240-50 [[18782641](#)]

Buse JB, Drucker DJ, Taylor KL, Kim T, Walsh B, Hu H, Wilhelm K, Trautmann M, Shen LZ, Porter LE DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. *Diabetes Care* 2010;33:1255-61 [[20215461](#)] [10.2337/dc09-1914](#)

Entry terms: exenatide, exenatide, bydureon, exendin-4, Ex4 peptide, exendin 4, AC 2993 LAR, Byetta, AC 2993,